COMMUNIQUÉS West-GlobeNewswire

-
Bio-Path Holdings Reports Full Year 2024 Financial Results
28/03/2025 -
CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates
28/03/2025 -
Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS
28/03/2025 -
60 Degrees Pharmaceuticals Announces 2024 Annual Results
28/03/2025 -
Winstrol Steroid: Benefits, Side Effects, Results & Buy Winstrol Pills Alternatives From CrazyBulk
28/03/2025 -
Ligandrol (LGD-4033) SARMs: Benefits, Results & Buy Ligandrol Pills Alternatives From CrazyBulk
28/03/2025 -
ProvaDent Reviews (Is It Safe And Legit?) Investigative Report On Ingredients, Side Effects, And Benefits!
28/03/2025 -
Pharming Group to participate in April investor conferences
28/03/2025 -
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
28/03/2025 -
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
28/03/2025 -
Communiqué de presse : Le Dupixent devient le tout premier biomédicament approuvé au Japon pour le traitement de la BPCO
28/03/2025 -
Curium Completes the Acquisition of Monrol as Part of its Plan to Significantly Expand Lutetium-177 Capacity and PET Footprint
28/03/2025 -
DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved
28/03/2025 -
DBV Technologies Annonce un Financement pouvant atteindre 306,9 millions de dollars (284,5 millions d’euros) permettant d’avancer le programme Viaskin® Peanut jusqu’au dépôt d'une Demande de Licence Biologique (BLA) et d’assurer la...
28/03/2025 -
VitalHub Reports Fourth Quarter and Annual 2024 Results
27/03/2025 -
Spectral AI Announces 2024 Fourth Quarter and Full Year Financial Results
27/03/2025 -
Beta Bionics Announces Board Appointment of Gerard Michel
27/03/2025 -
Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE
27/03/2025 -
Tilray Brands, Inc. to Announce Third Quarter Fiscal 2025 Financial Results on April 8, 2025
27/03/2025
Pages